Beranda › Kanker Mulut › Arkansas › Little Rock
Uji klinis Kanker Mulut di Little Rock, AR
4 studi untuk Kanker Mulut mencari peserta di lokasi sekitar Little Rock (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Menerima pesertaFase 3
- University of Arkansas for Medical Sciences, Little Rock
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Menerima pesertaFase 2
- University of Arkansas for Medical Sciences, Little Rock
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Menerima pesertaFase 2
- CARTI Cancer Center, Little Rock
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Menerima pesertaFase 2/3
- University of Arkansas for Medical Sciences, Little Rock
Uji klinis Kanker Mulut di kota lain
- Atlanta, GA9 studi
- St. Louis, MO8 studi
- New York City, NY8 studi
- Chicago, IL8 studi
- Durham, NC7 studi
- Houston, TX7 studi
- Ann Arbor, MI7 studi
- Portland, OR7 studi
- Pittsburgh, PA7 studi
- Milwaukee, WI7 studi
- Kansas City, MO7 studi
- Richmond, VA7 studi
Studi lain di Little Rock
- Skizofrenia19 studi
- Kanker (semua jenis)14 studi
- Gangguan Depresi Mayor14 studi
- Leukemia Mieloid Akut13 studi
- Kanker Paru Non-Sel Kecil13 studi
- Obesitas11 studi
- Kanker Endometrium10 studi
- Depresi10 studi
- Diabetes Tipe 210 studi
- Kanker Paru9 studi
- Penyakit Kardiovaskular9 studi
- Kanker Kandung Kemih9 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.